Vaccines

vaccines

Human Monoclonal Antibodies to Infectious Diseases

Using human B cell hybridoma creation, and antibody engineering technologies, Dr. James E Crowe Jr.'s laboratory has developed an array of antibodies from full length human antibodies to Fab fragments and diabodies. Many of these antibodies are ready for a cooperate partner who can further develop these antibodies into biologic herapeutics. The table below is a sample of the antibodies they are currently researching and have available. In addition to these areas of research, Dr. Crowe is actively seeking collaborative opportunities to identify new interesting targets for future antibody engineering projects.

Summary

Using human B cell hybridoma creation, and antibody engineering technologies, Dr.

Licensing manager: 
Hassan Naqvi
Read more

Live Attenuated Coronavirus Vaccines

The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations.
Licensing manager: 
Mike Villalobos
Read more

Neutralizing Human Monoclonal Antibody Against Respiratory Syncytial Virus

The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.

Summary

Using human B cell hybridoma creation, and antibody engineering technologies, Dr.

Licensing manager: 
Hassan Naqvi
Read more

Plasmid Based Reverse Genetics for Reovirus

Scientists at Vanderbilt have developed an entirely plasmid-based system to better utilize reoviruses as a research tool. The system allows for generating a reovirus entirely from cloned cDNAs comprising three steps involving fairly well-known techniques.

Technical Background:

Licensing manager: 
Hassan Naqvi
Read more

Featured Video

Vanderbilt Patent Activity

View Vanderbilt University Patents

CTTC on Twitter